Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call
March 23 2022 - 8:00AM
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage
biopharmaceutical company focused on the discovery, development and
commercialization of innovative therapies for diseases of the eye,
today announced that it will report fourth quarter and full year
2021 financial results on Tuesday, March 29, 2022. Management will
host a conference call and live audio webcast to discuss these
results and provide a business update at 8:00 a.m. ET.
The dial-in numbers to access the conference call
are 866-300-4091 (domestic) or 703-736-7433 (international) using
the conference ID 7368936. To access a live webcast and subsequent
archived recording of the call, please visit “Events” in the
“Investors” section on the Kala website at http://kalarx.com/.
About Kala Pharmaceuticals,
Inc.
Kala is a commercial-stage biopharmaceutical
company focused on the discovery, development, and
commercialization of innovative therapies for diseases of the eye.
Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP)
Drug Delivery Technology to two ocular therapies, EYSUVIS®
(loteprednol etabonate ophthalmic suspension) 0.25% and INVELTYS®
(loteprednol etabonate ophthalmic suspension) 1%. Kala also has a
pipeline of development programs including a clinical-stage
secretome product candidate, KPI-012, initially targeting
persistent corneal epithelial defects (PCED) and multiple
proprietary new chemical entity (NCE) preclinical development
programs targeted to address unmet medical needs, including both
front and back of the eye diseases. For more information on Kala,
please visit www.kalarx.com.
Investor Contacts: Jill
Steierjill.steier@kalarx.com 781-996-5252
Hannah Deresiewiczhannah.deresiewicz@sternir.com
212-362-1200
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From May 2024 to Jun 2024
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From Jun 2023 to Jun 2024